Combination Therapy With Exenatide Plus PioglitazoneVersus Basal / Bolus Insulin in Poorly Controlled Patients With Type 2 Diabetes on Sulfonylurea Plus Metformin : The Qatar Study
暂无分享,去创建一个
R. DeFronzo | M. Zirie | A. Jayyousi | M. Abdul-Ghani | C. Triplitt | John Adams | O. Migahid | A. Megahed | J. Adams
[1] Simon R. Heller,et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.
[2] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[3] M. Matsuda,et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. , 2007, American journal of physiology. Endocrinology and metabolism.
[4] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[5] R. DeFronzo,et al. Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations. , 1990, Metabolism: clinical and experimental.
[6] P. Raskin,et al. Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes , 2009, Diabetes Care.
[7] L. Ji,et al. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti‐hyperglycaemic medication: results of the PARADIGM study , 2012, Diabetic medicine : a journal of the British Diabetic Association.
[8] R. DeFronzo,et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial , 2015, Diabetes, obesity & metabolism.
[9] John B Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[10] G. Moneta. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialDormandy JA, for the PROactive investigators (St Georges Hosp, London; et al) Lancet 366:1279–1289, 200 , 2007 .
[11] UK Prospective Diabetes Study Group. UK prospective diabetes study (UKPDS) , 2004, Diabetologia.
[12] M. Hanefeld,et al. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study* , 2006, Current medical research and opinion.
[13] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[14] R. DeFronzo,et al. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.
[15] D. Owens,et al. Comparison between a basal‐bolus and a premixed insulin regimen in individuals with type 2 diabetes–results of the GINGER study , 2010, Diabetes, obesity & metabolism.
[16] M. Taskinen,et al. Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes , 2011, Diabetes Care.
[17] R. Klein,et al. Relation of Glycemic Control to Diabetic Microvascular Complications in Diabetes Mellitus , 1996, Annals of Internal Medicine.
[18] P. J. Berry. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years , 1995, BMJ.
[19] J. Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[20] T. Buchanan,et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. , 2006, Diabetes.
[21] R. DeFronzo,et al. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. , 2004, The Journal of clinical endocrinology and metabolism.
[22] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[23] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[24] S. Inzucchi,et al. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.
[25] S. Haffner,et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.
[26] D. Drucker. The biology of incretin hormones. , 2006, Cell metabolism.
[27] Devjit Tripathy,et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. , 2011, The New England journal of medicine.
[28] Y. Omori,et al. Glycemic Control and Prevention of Retinopathy in Japanese NIDDM Patients: A 10-year follow-up study , 1997, Diabetes Care.
[29] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[30] Yerong Yu,et al. Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance. , 2006, Diabetes research and clinical practice.
[31] E. Reece,et al. Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. , 2007, American journal of physiology. Endocrinology and metabolism.
[32] S. Colagiuri,et al. The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.
[33] Ralph A. DeFronzo,et al. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.
[34] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.